Program Overview
The biophyle Trial Accelerator is designed for:
- Companies in late-stage preclinical studies planning to enter Phase I or Phase II clinical trials within 12 months of entry into the program.
- Seeking an expedited clinical trial with renowned principal investigators and diverse patient populations
Our Focus
Advanced and emerging therapeutic modalities applied to serious and life-threatening diseases
- Modalities of interest include precision medicines, biologics, cell therapies, and genetic medicines
- Disease areas of interest include oncology, immunology, and cardiometabolic diseases
How it works:
- 1 Companies worldwide will be recruited to apply to the program.
- 2 Applications are reviewed as they are received by the biophyle team, and routed to clinical trial sites for additional reviews.
- 3 Companies are evaluated by clinical trial sites for feasibility and potential to improve outcomes.
- 4 Clinical sites will choose the trials they would like to conduct, and our clinical trial operations team will work with each of the selected companies to facilitate their clinical trial.
- Frequently Asked Questions
Our Team:
About Our Organizations
SymBiosis Capital Management, LLC is an investment firm focused on advancing biotherapeutics innovations. Led by Chidozie Ugwumba, Managing Partner, along with an experienced team of professionals, SymBiosis invests across disease area, financing stage, and geography, with a focus on programs in, or about to enter, human trials. The firm currently manages a portfolio of more than 30 investments and has significant, long-term capital commitments to fund future investments. For more information, please visit www.symbiosis.vc or follow us on LinkedIn.
HealthTech Arkansas is an organization that helps drive innovation for the ten largest hospitals and health systems in Arkansas, which they accomplish through accelerator programs and internal innovation programming. The firm’s flagship program, HeartX, is an annual accelerator currently focused on cardiovascular technologies. The program guarantees at least two hospital pilot projects or clinical trials for each early-stage company admitted to the program.
In addition to the guaranteed pilots, participating companies receive upfront investment from the HealthTech Arkansas Fund. The company’s internal innovation programming is focused on helping the state’s healthcare provider organizations to harvest, organize and develop ideas for new innovations from their own clinicians and administrators. The organization does this through a variety of specific programs focused on solving real problems and challenges (clinical and administrative in nature) through the development and commercialization of intellectual property to be owned by the provider organization.